Antoni Wiedlocha funded by the EEA Poland-Norway grants
The proposal "Novel targeted therapy based on dual warhead conjugates against FGFR dependent cancers", with senior scientist Antoni Wiedlocha at Department of Molecular Cell Biology, Institute for Cancer Research, as Norwegian partner and professor Jacek Otlewski at the University of Wroclaw as Polish parther, has been awarded funding from the EEA Poland-Norway grants under the "Applied Research" programme.
Links:
From the National Centre for Research and Development in Poland:
Published in Level 2 journals, first or last author from Oslo University Hospital.
Zeller B, Arad-Cohen N, Cheuk D, De Moerloose B, Navarro JMF, Hasle H, Jahnukainen K, Juul-Dam KL, Kaspers G, Kovalova Z, Jonsson OG, Lausen B, Munthe-Kaas M, Nystrom UN, Palle J, Pasauliene R, Pronk CJ, Saks K, Tierens A, Abrahamsson J(2024) Management of hyperleukocytosis in pediatric acute myeloid leukemia using immediate chemotherapy without leukapheresis: results from the NOPHO-DBH AML 2012 Protocol Haematologica(in press) DOI 10.3324/haematol.2024.285285, PubMed 38721737
Halvorsen B, Viermyr HK, Ueland T, Sagen EL, Michelsen AE, Bjerkeli V, Nor-Solidarity Study Group, Tveita AA, Henriksen KN, Kåsine T, Dyrhol-Riise AM, Trøseid M, Dahl TB, Aukrust P, Gregersen I(2024) IL-22 is increased in hospitalized patients with COVID-19 and associates with cardiac involvement J Infect, 106176(in press) DOI 10.1016/j.jinf.2024.106176, PubMed 38719108
Alehagen U, Alexander J, Aaseth JO, Larsson A, Opstad TB(2024) Supplementation with selenium and coenzyme Q10 in an elderly Swedish population low in selenium - positive effects on thyroid hormones, cardiovascular mortality, and quality of life BMC Med, 22(1), 191 DOI 10.1186/s12916-024-03411-1, PubMed 38714999